Zevra Therapeutics, Inc. Common Stock (ZVRA)
Zevra Therapeutics, Inc. (ZVRA) is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. The company aims to create innovative treatments by leveraging its expertise in neuropharmacology, targeting unmet medical needs in areas such as movement disorders and pain management.
Company News
Zevra Therapeutics announced granting options to purchase 38,000 shares of common stock to two new employees under its 2023 Employment Inducement Award Plan, with options vesting over four years.
Zevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, strengthening its balance sheet and supporting its strategic priorities.
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?